INTRODUCTION
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder. One of the pathological features of AD is the oligomerization and aggregation and accumulation of amyloidb peptide (Ab), forming amyloid plaques in the brain. Cognitive impairment observed in clinical AD is inversely well correlated with the amount of Ab oligomers in the soluble fraction rather than the amount of Ab fibrils (amyloid plaques) constituting the oligomers (Haass and Selkoe, 2007; Krafft and Klein, 2010) . Increasing evidence has shown that Ab oligomers extracted from AD model mice or made from synthetic peptides cause (E) Ab40 and Ab42 secreted from iPSC-derived neural cells into the medium (extracellular Ab) were measured at 48 hr after the last medium change. Data represent mean ± SD (n = 3 per clone). Levels of Ab40 and Ab42 in AD(APP-E693D) without b-secretase inhibitor IV (BSI, 1 mM) were significantly lower than those of the others (*, p < 0.006), and the level of Ab42 and the ratio of Ab42/Ab40 in AD(APP-V717L) without BSI were significantly higher than those of the others (legend continued on next page)
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Modeling Alzheimer's Disease with Patient iPSCs neurotoxicity and cognitive impairments in vitro and in vivo (Walsh et al., 2002; Gong et al., 2003; Lesné et al., 2006) , and this was also true in humans (Kuo et al., 1996; Shankar et al., 2008; Noguchi et al., 2009) . Therefore, the formation and accumulation of Ab oligomers has been presumed to play a central role in the pathogenesis and clinical symptoms of AD. Abs are composed of 38-43 amino acid residues and are generated from the amyloid precursor protein (APP) by b-and g-secretase-mediated sequential cleavages. A number of mutations linked to familial AD in the APP gene have been identified. Recently, an atypical early-onset familial AD, caused by an E693D mutation of an APP-producing variant Ab lacking 22 nd Glu was discovered in Japan (Tomiyama et al., 2008) . This APP-E693D mutation presents rare, autosomal-recessive mutations of the APP gene related to familial AD. Patients with the mutation show overt early-onset symptoms of AD but lack Ab deposition, according to positron emission tomography (PET) scan analysis with a [
11 C] Pittsburgh compound-B (PIB) radioprobe (Tomiyama et al., 2008; Shimada et al., 2011) . The 22 nd Glu within the Ab sequence has a destabilizing effect on the formation of oligomeric structures because of the electrostatic repulsion between the adjacent side chain of 22 nd Glu (Kassler et al., 2010) , and the deletion of the amino acid residue leads to the ready formation of Ab oligomers in vitro (Nishitsuji et al., 2009) . APP-E693D transgenic mice show AD-like pathology, including intracellular oligomer accumulation, but lack extracellular amyloid plaque formation (Tomiyama et al., 2010) . However, it remains unclear whether Ab oligomers are accumulated in familial and sporadic AD patient neural cells and how intracellular Ab oligomers play a pathological role. The compound and/or drugs that might rescue the Ab oligomer-induced pathological phenotypes are also unclear. Recent developments in induced pluripotent stem cell (iPSC) technology have facilitated the investigation of phenotypes of patient neural cells in vitro and have helped to overcome the lack of success in modeling sporadic AD. Here, we report the derivation and neuronal and astroglial differentiation of iPSCs from a familial AD patient with an APP-E693D mutation, a familial case with another APP mutation, as well as other sporadic cases. Using patient neurons and astrocytes, we addressed the accumulation and possible pathological roles of intracellular Ab oligomers in familial and sporadic AD. We found that Ab oligomers were not proteolytically resistant and that docosahexaenoic acid (DHA) treatment attenuated cellular phenotypes of AD neural cells with intracellular Ab oligomers in both familial and sporadic AD patients.
RESULTS
iPSC Generation and Cortical-Neuronal Differentiation Dermal fibroblasts were reprogrammed by episomal vectors (Okita et al., 2011) . Control iPSC lines from three unrelated individuals, three and two familial AD iPSC lines from patients with E693D[AD(APP-E693D)] and V717L[AD(APP-V717L)] APP mutations, respectively, and two sporadic iPSC lines (AD3E211 and AD8K213) from two unrelated patients (Figure S1A available online) were generated ( Figures 1A, 1B , and S1B-S1H). To characterize cortical neurons derived from the iPSC lines, we established differentiation methods for cortical neurons by modifying previous procedures (Figure S1I ). The differentiated cells expressed the cortical neuron subtype markers SATB2 and TBR1 ( Figure 1C) , and the differentiated neurons were functionally active ( Figures S1J and S1K ). There was no prominent difference in the differentiation propensity between control and AD neurons ( Figures 1D and S1L) .
We analyzed the amounts of extra-and intracellular Ab40 and Ab42 ( Figures 1E and 1F ). As expected, both Ab species were strongly decreased in all cloned AD(APP-E693D) neural cells in comparison to those in control neural cells. In familial AD(APP-V717L) neural cells, an increase in the extracellular Ab42 level and a corresponding decrease in the intracellular Ab42 level were observed, and the Ab42/Ab40 ratio in the culture medium was increased up to 1.5-fold, suggesting that the abnormality of APP metabolism in AD is dependent on the mutation sites in APP. Extracellular Ab levels in sporadic AD neural cells were not changed in comparison to those in control neural cells, but intracellular Ab in sporadic AD8K213 neural cells apparently decreased (that is, below the detection limit). APP expression levels in the AD(APP-E693D) neural cells were lower than in the others, but the levels of a-and b-secretase-mediated APP processing remained unaltered in all neural cells (Figures 1G, S1M, and S1N). Soluble APPb production was strongly inhibited by treatment with b-secretase inhibitor IV (BSI) ( Figure 1G ). Ab levels in the original fibroblasts and iPSC-derived astrocytes, in which APP expression levels were relatively higher than those in neural cells (data not shown), were lower than those of the corresponding neural cells (Figures S1O and S1P) .
Intracellular Accumulation of Ab Oligomers in AD(APP-E693D) and in One of the Sporadic AD Neural Cells Using an immunocytochemical method with the Ab-oligomerspecific antibody NU1 (Lambert et al., 2007) , we investigated whether AD(APP-E693D) neural cells harbor Ab oligomers or not. We found that Ab oligomers were accumulated as puncta in the neurons of AD(APP-E693D) and in one of the sporadic AD cases (Figure 2A ). The area of Ab-oligomer-positive puncta was significantly increased in AD(APP-E693D) neuronal cells relative to control neuronal cells ( Figure 2B ). Dot blot analysis using cell lysates revealed that Ab oligomers were markedly elevated in the AD(APP-E693D) and sporadic AD8K213 neural cells ( Figures 2C and 2D ), whereas Ab oligomers were not detected in the culture medium (data not shown). Another antibody against Ab, 11A1, which detects low-molecular-weight oligomers rather than the Ab monomer (Murakami et al., 2010) , showed results similar to those observed with NU1 (Figures (legend continued on next page)
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Modeling Alzheimer's Disease with Patient iPSCs S2A-S2D). However, Ab oligomers were not detected in cell lysates from the fibroblasts that generate iPSC lines ( Figure S2E ). To confirm whether Ab oligomers were derived from mutant APP(E693D), we transduced a lentiviral vector driven by an EF1a promoter to overexpress wild or mutant APP(E693D) in control iPSC-derived neural cells and found that Ab oligomers emerged inside control neural cells overexpressing mutant APP(E693D) ( Figure S2F ).
To investigate the intracellular accumulation of Ab oligomers in astrocytes derived from control and AD iPSCs, we established an astrocyte-enrichment culture by modifying the method previously reported (Krencik et al., 2011) (Figures S2G-S2J ). Dot blot analysis using Ab oligomer antibodies revealed that the astrocytes of AD(APP-E693D) and one of the sporadic AD iPSCs accumulated Ab oligomers intracellularly ( Figures 2E, S2K , and S2L), which was compatible with the results of neurons. On the other hand, we detected no difference in the uptake of extracellular glutamate between control and AD astrocytes ( Figure S2M ).
Ab oligomers were also detected as a protein band with a molecular mass of 5060 kDa by western blot analysis ( Figures  2F and S2N ). The accumulation of Ab oligomers was inhibited by treatment with BSI ( Figures 2A-2G , S2A-S2D, and S2N). To clarify whether the E693D mutation results in accelerated Ab oligomerization and/or in a proteolytically resistant and stable form of Ab oligomers, we analyzed the levels of Ab oligomers over a course of time after BSI treatment. Intracellular Ab oligomers started to disappear from 2 hr after the treatment with BSI, almost reaching the control level by 8 hr (Figures 2G and 2H) . Secretion of Ab40 from control neural cells was already inhibited at 2 hr after BSI treatment, but the secretion from AD neural cells was under the detection limit in both the presence and absence of BSI ( Figure 2I ).
Cellular Stress Responses Caused By Intracellular Ab
Oligomers in AD iPSC-Derived Neural Cells Extracellular Ab deposition in patient brains carrying APP with an E693D mutation is predicted to be extremely low, as amyloid PET imaging with a [ 11 C] PIB probe revealed a far lower signal in the patients than those observed in sporadic AD brains (Tomiyama et al., 2008) . Given that processing by b-and g-secretases largely proceeds within vesicular endosomal compartments, it was possible that Ab oligomers were associated with specific organelles. We characterized the Ab oligomer-positive punctate structures in AD(APP-E693D) neural cells and astrocytes by coimmunostaining with antibodies for markers of vesicular compartments and subcellular organelles. Subpopulations of Ab oligomer-positive puncta in the AD neurons showed positive immunostaining for an endoplasmic reticulum (ER) marker, binding immunoglobulin protein (BiP); an early endosomal marker, early endosome-associated antigen-1 (EEA1); and a lysosomal marker, lysosomal-associated marker protein 2 (LAMP2) (data not shown).
To uncover molecules that might be implicated in the dysfunction of AD(APP-E693D) neural cells, we analyzed gene expression profiles of control and AD neural cells ( Figure 3A and Table  S1 ). Gene ontology analysis revealed that oxidative-stressrelated categories, including peroxiredoxin, oxidoreductase, and peroxidase activities, were upregulated in the AD, whereas glycosylation-related categories were downregulated (Figures 3B and 3C and Table S1 ), suggesting that ER and Golgi function might be perturbed in AD neural cells. Western blot analysis clarified that the amounts of both BiP and cleaved caspase-4 were elevated in the neurons and astrocytes of the AD(APP-E693D) case, and that of BiP in one of the sporadic AD cases, AD8K213, but not in fibroblasts ( Figures 3D-3F and S3A-S3F). We also found that BSI treatment not only prevented the increase in Ab oligomer-positive puncta area per cell in the context of AD(APP-E693D) lines but also decreased the amount of BiP and cleaved caspase-4 ( Figures 3D-3F ). PRDX4-coding antioxidant protein peroxiredoxin-4 was the most highly upregulated gene ( Figure 3C ). Western blot analysis confirmed that the amount of peroxiredoxin-4 was increased up to approximately 5-to 7-fold in lysates from AD(APP-E693D) and in one of the sporadic AD cases, AD8K213 neural cells, but not in fibroblasts, and was decreased by the BSI treatment ( Figures 3D, 3G , S3A, S3D, S3G, and S3H), indicating that the antioxidant stress response was provoked by Ab oligomer formation in AD(APP-E693D) and sporadic AD8K213. To identify pathogenic species evoking oxidative stress in AD(APP-E693D), we visualized reactive oxygen species (ROS) and found that ROS was increased in both neurons and astrocytes in AD(APP-E693D) and AD8K213 . This increase was counteracted by the BSI treatment. These results indicated that intracellular Ab oligomers provoked both ER and oxidative stress, and the increase in ROS most likely occurred via a vicious cycle between ER and oxidative stress (Malhotra and Kaufman, 2007) .
Alleviation of Intracellular Ab Oligomer-Induced Cellular
Stress by DHA We evaluated BSI and three additional drugs that had been reported to improve ER stress or to inhibit ROS generation: (1) DHA (Begum et al., 2012) , (2) dibenzoylmethane (DBM14-26) (Takano et al., 2007) , and (3) (Figures S4E-S4G ). In contrast, the high concentration of DHA, DBM14-26, or NSC23766 treatment increased the protein level of BiP ( Figure S4B ). Finally, to confirm the protective effects of DHA in short-term screening, we analyzed the effect on the survival of AD(APP-E693D) neural cells. Neuronal cells were labeled with a lentiviral vector expressing synapsin I-promoter-driven EGFP and cultivated in the medium depleted of neurotrophic factors and neural culture supplements mix. The real-time survival rate of AD(APP-E693D) neurons was lower than that of normal control neurons; however, DHA treatment for 16 days partially rescued AD(APP-E693D) cell viability ( Figures 4E-4G ). The real-time survival rate of sporadic AD(AD3E211, AD8K213) neurons for 16 days was unchanged (Figures 4E and 4F and Table S2 ). We confirmed these results through a lactate dehydrogenase (LDH) assay ( Figure 4G ). The AD(APP-E693D) neurons were also vulnerable to oxidative stress by hydrogen peroxide treatment (Figure S4H) . Extracellular Ab levels were not altered in the assay ( Figure 4H ).
DISCUSSION
The present study shows that neural cells derived from a patient carrying the pathogenic APP-E693D mutation and a sporadic AD patient produce intracellular Ab oligomers, and the use of these neural cells provided an experimental system for addressing whether such oligomers would cause cellular stress and the killing of neurons and how such intracellular Ab oligomers might contribute to the disease pathogenesis, despite only one patient carrying the E693D mutation being available. Our findings also suggest that the possible heterogeneity of familial and sporadic AD stems from phenotypic differences of intracellular Ab oligomers and suggests the possibility that DHA, a drug that failed in some clinical trials of AD treatment, might be effective in a portion of AD patients.
We demonstrated that Ab oligomers were formed and accumulated inside AD(APP-E693D) and sporadic AD(AD8K213) neurons by immunostaining (Figures 2A and 2B) , dot blot analysis ( Figures 2C and 2D) , and western blot analysis ( Figures 2F  and S2N ). In addition, intracellular accumulation of Ab oligomers, which has been supposed to be proteolytically resistant, disappeared after treatment with BSI in both AD neurons ( Figures 2G and 2H ), indicating that AD(APP-E693D) and sporadic AD(AD8K213) neurons still seemed to retain a degrading activity toward Ab oligomers in which proteasomes, autophagosomes, and/or lysosomes may be involved and, thereby, that the pathological property of Ab oligomers in a part of AD might be completely abrogated. The sporadic AD(AD8K213) neurons may retain a specific cellular environment that permits the formation of Ab oligomers. Additional studies aimed at identifying the factors causing such an environment are needed.
We observed that the accumulation of Ab oligomers induced ER and oxidative stress both in AD(APP-E693D) and in sporadic AD(AD8K213) neurons, although caspase-4 activation appeared not to accompany sporadic AD, probably because of the lesser extent of ER stress in comparison to AD(APP-E693D). Previously, Nishitsuji et al. (2009) reported that accumulated Ab oligomers in ER provoke ER stress. This result suggests that oligomers represent a self-aggregating state of Ab. During this process, Ab generates ROS, which is supported by the fact that Ab coordinates the metal ions zinc, iron, and copper, which induce the oligomerization of Ab. Iron and copper then cause the generation of toxic ROS and calcium dysregulation (Barnham et al., 2004) , leading to membrane lipid peroxidation and the impairment of the function of a range of membrane-associated proteins (Hensley et al., 1994; Butterfield, 2003) , antioxidant factors being thought to protect ER-stress-induced cellular toxicities (Malhotra and Kaufman, 2007) .
We found that intracellular Ab oligomers were accumulated not only in a case of familial AD with APP-E693D mutation but also in a sporadic AD case, although only three clones derived from one familial AD patient carrying an APP-E693D mutation and two clones from two sporadic AD patients were analyzed in this study because of the limited number of patients. In contrast, in familial AD with the APP-V717L mutation, of which only one case was available, intracellular Ab oligomers were not detected, but the extracellular Ab42/Ab40 ratio, which is increased in mutant presenilin-mediated familial AD, as reported previously (Yagi et al., 2011) , was increased, lending support to the notion that AD could be classified into two categories: extracellular Ab type and intracellular Ab type. Although it has been supposed that environmental factors and/or the aging process contribute to neurodegenerative diseases, our findings support the idea that a genetic factor might play a role in a part of sporadic AD, a finding that is compatible with a previous report (Israel et al., 2012) . However, identifying the genetic factor would require a larger sample size. The sporadic AD case with intracellular Ab oligomers might correspond to the case without extracellular Ab40 elevation of Israel et al. (2012) . Analysis of neurons (I and J) Quantitative data of (H), ROS-HPF (I), and ROS-CellROX (J). Each value was shown as a ratio of the HPF-stained or CellROX area (average of random 25 fields per sample) adjusted with DAPI counts. Data represent mean ± SD (n = 3 per clone). ROS-generation levels in AD(APP-E693D) and sporadic AD(AD8K213) neural cells were significantly different from those of the others (**, p < 0.001). Data represent mean ± SD (n = 3 per clone). See also Figure S3 and Table S1 .
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To date, the clinical effectiveness of DHA treatment is still controversial (Freund-Levi et al., 2006; Quinn et al., 2010) . It is of particular interest that one of two sporadic AD neurons accumulated intracellular Ab oligomers and showed cellular phenotypes that could respond to DHA but the other did not, and this result may explain why DHA treatment was effective for some AD patients, those with the intracellular Ab oligomer-associated type of AD, although the timing (that is, the stage of disease development) for starting the treatment would be another critical factor. These results may suggest that patient-specific iPSCs provide a chance to re-evaluate the effect of a drug that failed in AD clinical trials, depending on the selection of the patient type. In the present study, the amount of Ab oligomers in our culture was not affected by DHA, although it would be effective for reducing cellular stresses, and reducing the oligomerization of Ab was also presumed to be a candidate mechanism of DHA treatment (Cole and Frautschy, 2006) . These results indicate that therapy with DHA would alleviate symptoms. Furthermore, the data showing that BSI treatment leads to a reduction in ROS formation at a relatively similar level ( Figure 2G ) in both AD and control cells might indicate an Ab oligomer-independent effect, in addition to an Ab oligomer-dependent effect, of BSI.
In any event, patient-specific iPSCs would provide disease pathogenesis, irrespective of the disease being in a familial or sporadic form, as well as enable the evaluation of drug and patient classification of AD.
EXPERIMENTAL PROCEDURES
Derivation of Patient-Specific Fibroblasts
Control and AD-derived human dermal fibroblasts (HDFs) were generated from explants of 3 mm dermal biopsies. After 1-2 weeks, fibroblast outgrowths from the explants were passaged.
iPSC Generation Human complementary DNAs for reprogramming factors were transduced in HDFs with episomal vectors (SOX2, KLF4, OCT4, L-MYC, LIN28, and small hairpin RNA for p53). Several days after transduction, fibroblasts were harvested and replated on an SNL feeder cell layer. On the following day, the medium was changed to a primate embryonic stem cell medium (ReproCELL, Japan) supplemented with 4 ng/ml basic FGF (Wako Pure Chemicals Industries, Japan). The medium was changed every other day. iPSC colonies were picked up 30 days after transduction.
Statistical Analysis
All data are shown as mean ± SD. For comparisons of the mean between two groups, statistical analysis was performed by applying Student's t tests after confirming equality between the variances of the groups. When the variances were unequal, Mann-Whitney U tests were performed (SigmaPlot 11.2.0, Systat Software, USA). Comparisons of the mean among three groups or more were performed by one-way, two-way, or three-way analysis of variance followed by a post hoc test with the use of Student-Newman-Keuls Method (SigmaPlot 11.2.0). p values < 0.05 were considered significant.
ACCESSION NUMBERS
The Gene Expression Omnibus accession numbers for microarray data reported in this paper are GSE43326 (gene-expression comparison between control and AD clones), GSE43382 (gene-expression change along with the astroglial differentiation), and GSE43328 (gene-expression comparison of generated iPSCs). (C) is shown. Each value indicated the ratio of the CellROX-stained area (an average of random 25 fields per sample) adjusted with DAPI counts. Data represent mean ± SD (n = 3 per clone). Two-way ANOVA showed significant main effects of DHA treatment (F [1, 32] = 43.140; p < 0.001) with a significant interaction between the APP mutation and DHA treatment (F [3, 32] = 23.410; p < 0.001). The DHA group in AD(APP-E693D) neural cells was significantly different from the other groups (**, p < 0.005). (E) Real-time survival rate of control and AD neural cells with and without DHA showing cell viability. The numbers of control and AD(APP-E693D) neurons with Synapsin I-promoter-driven EGFP were sequentially imaged (average of 25 random fields per sample) and counted to assess the survival ratio (n = 3 per clone). Data represent mean ± SD (n = 3 per clone). In the cell-survival ratio, three-way ANOVA showed significant main effects of the APP mutation (F [1, 256] = 377.611; p < 0.001), DHA treatment (F [1, 256] = 36.117; p < 0.001), and time (F [7, 256] = 65.272; p < 0.001), with significant interactions between the APP mutation and DHA treatment (F [1, 256] = 18.315; p < 0.001), between the APP mutation and time (F [7, 256] = 20.023; p < 0.001), between DHA treatment and time (F [7, 256] = 4.534; p < 0.001), and among all three factors (F [7, 256] = 5.277; p < 0.001). Post hoc analysis revealed that, on day 14 and day 16, AD(APP-E693D) neural cells were more vulnerable in the long culture than control neural cells and that DHA treatment rescued the vulnerability (*, p < 0.001). (F) Typical images of Synapsin::EGFP neurons used in real-time survival assay. The scale bar represents 50 mm. (G) Cytotoxicity in neural culture derived from control and AD iPSCs after treatment with DHA (5 mM) for 16 days. Measured fluorescent lactate dehydrogenase (LDH) release served as a measure of cytotoxicity. Data represent mean ± SD (n = 3 per clone). Two-way ANOVA showed significant main effects of DHA treatment (F [1, 32] = 16.710; p < 0.001) with a significant interaction between APP-E693D mutation and DHA treatment (F [3, 32] = 9.210; p < 0.005). There was a significant difference in AD(APP-E693D) neural cells between the DMSO-control and DHA groups (*, p < 0.05). (H) Ab40 and Ab42 secreted from iPSC-derived neurons into medium (extracellular Ab) at day 16 of the long-term culture were measured at 48 hr after the last medium change. Data represent mean ± SD (n = 3 per clone). See also Figure S4 and Table S2 . (E) Dot-blot analysis using NU1 antibody, after treatment with vehicle or DHA at indicated concentrations.
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(F) Densitometric analysis of dot-blot analysis using NU1 antibody, with or without drug treatment. Data represent mean ± SD (n = 3 per group).
(G) Summary of effects of drugs. +, accumulated; -, not detected; ↑, increased; ↓, decreased; →, no significant change.
